Intravitreal anti-VEGF use not tied to systemic adverse events

March 26, 2018

(HealthDay)—Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is not associated with increased risk of systemic adverse events for patients with neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion, according to a review published online March 22 in JAMA Ophthalmology.

Marie Thulliez, M.D., from Bretonneau Hospital in Tours, France, and colleagues conducted a to examine systemic adverse events associated with intravitreal anti-VEGF treatments in patients with neovascular age-related macular degeneration, , or . Twenty-one systematic reviews were retrieved; 11 of these analyzed systemic adverse events as the primary outcome.

The researchers found that, compared with control regimens, anti-VEGF treatments did not increase the risk of systemic adverse events. The risk of systemic adverse events was also not increased when treatment was given on a monthly versus as-needed schedule. In the most recent and exhaustive reviews, bevacizumab was not associated with an increase in the risk of systemic adverse events compared with ranibizumab. In patients with age-related macular degeneration, ranibizumab may be associated with increased risk of nonocular hemorrhage compared with control treatments.

"This overview of reviews and meta-analyses suggest that anti-VEGF treatments do not increase the risk of systemic adverse events, but that caution might be advisable in older patients with who may be at higher risk of hemorrhagic events when receiving ranibizumab," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: Bevacizumab safe for use in Tx of macular degeneration

More information: Abstract/Full Text

Related Stories

Bevacizumab safe for use in Tx of macular degeneration

September 29, 2014
(HealthDay)—The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD), according to research published online Sept. 15 ...

Repeated ranibizumab doesn't impair macular perfusion

March 7, 2018
(HealthDay)—For patients with diabetic macular edema, repeated ranibizumab treatment does not appear to be associated with impaired macular perfusion, according to a study published online March 1 in JAMA Ophthalmology.

Persistent DME more likely with bevacizumab treatment

February 4, 2018
(HealthDay)—For patients with diabetic macular edema (DME), persistence is more likely with bevacizumab than with aflibercept or ranibizumab, according to a study published online Feb. 1 in JAMA Ophthalmology.

Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma

March 16, 2017
Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study published online by JAMA Ophthalmology.

World's largest clinical specialty database yields critical insights

November 13, 2017
The American Academy of Ophthalmology today announced key milestones and clinical insights from studies powered by its clinical database. The IRIS Registry (Intelligent Research In Sight) has amassed more than 41.2 million ...

Study finds biomarker that predicts who responds best to common diabetic complication

March 8, 2018
Researchers at St. Michael's Hospital have found a biomarker from fluid in the eye that predicts which patients will respond best to current treatments for diabetic macular edema, one of the most common complications of diabetes.

Recommended for you

Scientists combine technologies to view the retina in unprecedented detail

November 14, 2018
By combining two imaging modalities—adaptive optics and angiography—investigators at the National Eye Institute (NEI) can see live neurons, epithelial cells, and blood vessels deep in the eye's light-sensing retina. Resolving ...

Eyepatch with dissolvable needles used to treat eye disease

November 12, 2018
A team of researchers affiliated with several institutions in Singapore has developed an eyepatch with dissolvable needles for use in treating eye diseases. In their paper published in the journal Nature Communications, the ...

Calcifications in the eye increase risk for progression to advanced AMD by more than six times

November 8, 2018
Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration (AMD). Experts from Queen's University Belfast, working in partnership with the University of Alabama of Birmingham ...

Traditional glaucoma test can miss severity of disease

November 8, 2018
The most common tests for glaucoma can underestimate the severity of the condition by not detecting the presence of central vision loss, according to a new Columbia University study.

New contact lens to treat eye injuries

November 5, 2018
A new therapeutic contact lens that acts as a bandage for eye surface injuries being developed by QUT researchers could soon fast track the healing of previously difficult to treat corneal wounds.

New study offers hope for patients suffering from a rare form of blindness

November 1, 2018
A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness. This hyper-targeted approach offers hope to individuals living with spinocerebellar ataxia ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.